NCT02737397View on ClinicalTrials.gov

Safety and Efficacy of a Combination Product for the Prevention of Veisalgia

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Veisalgia
Interventions
DRUG

JMI-001 (SJP-304 and SJP-223)

DRUG

SJP-304

DRUG

SJP-223

DRUG

placebo

Sponsors
All Listed Sponsors
lead

Sen-Jam Pharmaceutical

OTHER

NCT02737397 - Safety and Efficacy of a Combination Product for the Prevention of Veisalgia | Biotech Hunter | Biotech Hunter